Grass Pollen Allergy - Pipeline Review, H1 2020
Grass Pollen Allergy - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2020, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.
Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 4 and 2 respectively.
Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2020, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.
Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 4 and 2 respectively.
Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Grass Pollen Allergy - Overview
Grass Pollen Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Grass Pollen Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Grass Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergy Therapeutics Plc
ASIT Biotech SA
Biomay AG
DC4U BV
HAL Allergy BV
Regeneron Pharmaceuticals Inc
Grass Pollen Allergy - Drug Profiles
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gp-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Grass - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Grass Pollen Allergy - Dormant Projects
Grass Pollen Allergy - Discontinued Products
Grass Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Dec 20, 2019: ASIT biotech discloses next steps following gp-ASIT+ phase III results
Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme
Nov 25, 2019: ASIT biotech gp-ASIT+ phase III trial in Grass Pollen Allergy did not meet the primary endpoint
Oct 17, 2019: ASIT biotech mode of action study of gp-ASIT+ for Grass Pollen Allergy published in The Journal of Allergy and Clinical Immunology (JACI)
Sep 26, 2019: ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy
Sep 05, 2019: Successful pollen season confirms Asit Biotech on track for phase III results of gp-ASIT+ in December 2019
Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial
May 02, 2019: ASIT biotech announces the achievement of new clinical and corporate development milestones
Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update
Mar 29, 2019: ASIT biotech’s scientific advisory boards (SAB) provide positive recommendations on the clinical development of gp-ASIT+
Mar 05, 2019: ASIT biotech Reveals the Mode of Action of Its Lead Immunotherapy Product for Allergic Rhinitis, gp-ASIT+, in The Journal of Allergy and Clinical Immunology (JACI)
Jan 31, 2019: First patient treated with gp-ASIT+ within the framework of the confirmatory Phase III study in grass pollen rhinitis
Jan 16, 2019: Ongoing Restructuring of ASIT biotech Organization to Maximize the Success of gp-ASIT+ in Grass Pollen Rhinitis
Nov 19, 2018: ASIT biotech launches its confirmatory phase III clinical study with gp-ASIT+ in grass pollen rhinitis prevention following the investigator meeting hosted in Prague (Czech Republic)
Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Grass Pollen Allergy - Overview
Grass Pollen Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Grass Pollen Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Grass Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergy Therapeutics Plc
ASIT Biotech SA
Biomay AG
DC4U BV
HAL Allergy BV
Regeneron Pharmaceuticals Inc
Grass Pollen Allergy - Drug Profiles
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dupilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gp-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Grass - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Grass Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Grass Pollen Allergy - Dormant Projects
Grass Pollen Allergy - Discontinued Products
Grass Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Dec 20, 2019: ASIT biotech discloses next steps following gp-ASIT+ phase III results
Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme
Nov 25, 2019: ASIT biotech gp-ASIT+ phase III trial in Grass Pollen Allergy did not meet the primary endpoint
Oct 17, 2019: ASIT biotech mode of action study of gp-ASIT+ for Grass Pollen Allergy published in The Journal of Allergy and Clinical Immunology (JACI)
Sep 26, 2019: ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy
Sep 05, 2019: Successful pollen season confirms Asit Biotech on track for phase III results of gp-ASIT+ in December 2019
Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial
May 02, 2019: ASIT biotech announces the achievement of new clinical and corporate development milestones
Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update
Mar 29, 2019: ASIT biotech’s scientific advisory boards (SAB) provide positive recommendations on the clinical development of gp-ASIT+
Mar 05, 2019: ASIT biotech Reveals the Mode of Action of Its Lead Immunotherapy Product for Allergic Rhinitis, gp-ASIT+, in The Journal of Allergy and Clinical Immunology (JACI)
Jan 31, 2019: First patient treated with gp-ASIT+ within the framework of the confirmatory Phase III study in grass pollen rhinitis
Jan 16, 2019: Ongoing Restructuring of ASIT biotech Organization to Maximize the Success of gp-ASIT+ in Grass Pollen Rhinitis
Nov 19, 2018: ASIT biotech launches its confirmatory phase III clinical study with gp-ASIT+ in grass pollen rhinitis prevention following the investigator meeting hosted in Prague (Czech Republic)
Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Grass Pollen Allergy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Grass Pollen Allergy - Pipeline by ALK-Abello AS, H1 2020
Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2020
Grass Pollen Allergy - Pipeline by ASIT Biotech SA, H1 2020
Grass Pollen Allergy - Pipeline by Biomay AG, H1 2020
Grass Pollen Allergy - Pipeline by DC4U BV, H1 2020
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2020
Grass Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Grass Pollen Allergy - Dormant Projects, H1 2020
Grass Pollen Allergy - Discontinued Products, H1 2020
Number of Products under Development for Grass Pollen Allergy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Grass Pollen Allergy - Pipeline by ALK-Abello AS, H1 2020
Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2020
Grass Pollen Allergy - Pipeline by ASIT Biotech SA, H1 2020
Grass Pollen Allergy - Pipeline by Biomay AG, H1 2020
Grass Pollen Allergy - Pipeline by DC4U BV, H1 2020
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2020
Grass Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Grass Pollen Allergy - Dormant Projects, H1 2020
Grass Pollen Allergy - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Grass Pollen Allergy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
ALK-Abello AS
Allergy Therapeutics Plc
ASIT Biotech SA
Biomay AG
DC4U BV
HAL Allergy BV
Regeneron Pharmaceuticals Inc
Number of Products under Development for Grass Pollen Allergy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
ALK-Abello AS
Allergy Therapeutics Plc
ASIT Biotech SA
Biomay AG
DC4U BV
HAL Allergy BV
Regeneron Pharmaceuticals Inc
